Karyopharm to sell itself in bankruptcy, Ayrmid lead bidder

Karyopharm, maker of cancer drug Xpovio, will sell itself through a court-supervised auction in Chapter 11, with Ayrmid as stalking-horse lead bidder. Karyopharm reported about $115 million in 2025 Xpovio sales and faces $15.8 million in debt coming due; its shares fell 83%.

Why it matters: Karyopharm brought Xpovio to market but never turned a profit.